Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 20, 2018
Pharmacy Choice - News - Pharmaceutical Development - September 20, 2018

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/20/18 - Innovent Presents Clinical Data of Anti-PD-1 Antibody Sintilimab as the First-line Treatment for Patients with NSCLC at Annual Meeting of the Chinese Society of Clinical Oncology
Innovent Biologics, a world-class China- based biopharmaceutical company that develops and commercializes high quality drugs, today presented clinical trial data on cohort D of sintilimab clinical studies at the 2018 Annual Meeting of Chinese Society of Clinical Oncology. Based on the efficacy and safety profile from this early phase clinical tri
9/20/18 - MTEM Abuzz, TLRY Up 1,240% In 2 Months, ALT Awaits Anthrax Data In Q4
Gained 285.48% to close Wednesday's trading at $16.46. On September 14, the Company effected a 1 for 30 reverse stock split. On September 4, the Company announced additional positive data from a Phase 2 a study of its NasoVAX intranasal influenza vaccine candidate. Gained 55% to close Wednesday's trading at $8.68.
9/20/18 - Surgery Journal Issues Nine Research Articles in August 2018 Edition
Surgery, a peer-reviewed journal from the Association of VA Surgeons, Pacific Coast Surgical Association and Surgical Outcomes Club that promotes the art and science of surgery, published nine research articles on the following topics in its August 2018 edition:. *Association of Hospital Participation in a Regional Trauma Quality Improvement...
9/19/18 - $1.7 Million SBIR Grant Fast-tracks Faster Bone Fracture Healing ... Aims to Reduce Mortality and Improve Quality of Life for Aging Population
Purdue University issued the following news release:. A $1.7 million National Science Foundation SBIR Phase I/II grant to a Purdue University- affiliated startup will help fast-track to human trials a novel injectable-targeted drug that shows great promise in accelerating and improving the healing of broken or compromised bones. Novosteo Inc., the.
9/19/18 - [Ph.No.31021] Heavy Weight Cotton Crepe Bandage B.P. With Fast Edges 15 Cm X 3 Mtr (Stretched Length) Fda Approved
Address: Room No.312, IIIrd Floor, Railnilayam, Secunderabad-500071, Andhra Pradesh, Attn: Chief Administrative Officer. Description: Tenders are invited for Heavy Weight Cotton Crepe Bandage B.P. With Fast Edges 15 Cm X 3 Mtr Fda Approved Acms/Rh/Crs/Tpty Andhra Pradesh 225.00 Numbers Acms/Rh/Ryp Andhra Pradesh 100.00 Numbers Cms/Rh/Bza Andhra Pra
9/19/18 - 60 Biggest Movers From Yesterday
The study achieved primary endpoint. Navidea Biopharmaceuticals Inc shares climbed 60.06 percent to close at $0.2889 after the company reported acceptance into the National Institutes of Health Commercialization Accelerator Program. Tilray, Inc. surged 28.95 percent to close at $154.98 after the company received US approval to import a medical...
9/19/18 - AB Introduces Hassle Free MRI Cochlear Implant Technology
By a News Reporter-Staff News Editor at Biotech Week Advanced Bionics Announces the FDA Approval of the HiRes? Ultra 3 D Cochlear Implant. Built on the HiRes? Ultra platform and developed by the internal Research and Development Team at AB, the new implant is the Hassle Free and Pain Free choice for recipients undergoing MRI examinations. Han
9/19/18 - AbbVie Reinforces Leadership in Dermatology With New Data Showcasing Research Advancements Across Growing Portfolio at the 27th European Academy of...
AbbVie Reinforces Leadership in Dermatology With New Data Showcasing Research Advancements Across Growing Portfolio at the 27th European Academy of Dermatology and Venereology EADV Congress. By a News Reporter-Staff News Editor at Biotech Week AbbVie, a research-based global biopharmaceutical company, announced that it will present new data acros
9/19/18 - Acasti Pharma Provides Clinical and Market Update [Syrian Arab News Agency]
Acasti Pharma Inc., a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, today provided a clinical and market update. Jan DAlvise, president and CEO of Acasti Pharma, commented, I am pleased to report we remain on track wit
9/19/18 - Acerus Announces Publication of Manuscript Reporting Early Data from Partner-Sponsored Natesto Spermatogenesis Study
TORONTO- Acerus Pharmaceuticals Corporation today announced the publication of a clinical trial update in the journal European Urology Focus on the effects of Natesto on reproductive hormones and semen parameters. This study is being conducted at the University of Miami's Department of Urology, and Dr. Ranjith Ramasamy, MD, the Director of Reproduc
9/19/18 - Adverum Biotechnologies Receives Fast Track Designation for ADVM-022 Gene Therapy for the Treatment of wAMD
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced the U.S. Food and Drug Administration has granted Fast Track designation for ADVM-022. The FDA s Fast Track designation is an important recognition of our ADVM-022 gene therapy program, s
9/19/18 - Alector Initiates Phase 1 Trial of AL001 for the Treatment of Frontotemporal Dementia
Alector, a privately held biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the initiation of its Phase 1 trial called INFRONT, which is evaluating AL001, the company s product candidate for the treatment of a genetically-defined sub-population of patients with
9/19/18 - AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-PA01 Targeting Pseudomonas Aeruginosa Infections [Syrian Arab News Agency]
AmpliPhi Biosciences Corporation, a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the company has received positive feedback, via written response, from the U.S. Food and Drug Administration regarding its development plans for AB-PA01,...
9/19/18 - Amygdala Neurosciences Announces the $12.4 Million HEAL Initiative Sponsored SEARCH (Safety and Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People with Opioid Use Disorder) Program of Phase 2 Clinical Studies
Amygdala Neurosciences announced today the SEARCH program of Phase 2 clinical studies which are sponsored by the National Institute of Allergy and Infectious Diseases and are being conducted by the NIH Clinical Center and the Institute of Human Virology at the University of Maryland School of Medicine. Henry Masur, Chief of the NIH Critical Care
9/19/18 - Antibody Discovery: Services and Platforms Market (2nd Edition), 2018-2028
INTRODUCTION Given the increasing focus on personalized medicine, biologics have established a strong foothold in the pharmaceutical industry. Owing to several beneficial features, such as high specificity, and a favorable safety profile, antibody based pharmacological interventions presently represent the largest class of biologics, with 79...
9/19/18 - ApoCell Announces Publication of First Therapeutic Target Biomarker Correlation in Circulating Tumor Cells and Overall Survival in Patients with Solid Tumors
ApoCell, Inc., a leader in the capture and analysis of circulating tumor cells, announced today the publication of biomarker results from the BEACON Phase 3 clinical trial that utilized Apocell's proprietary circulating tumor cell enrichment system, ApoStream . ApoCell's proprietary ApoStream technology uses a low-level electrical field to capt
9/19/18 - ARCA biopharma Submits Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial [T-break Tech (Middle East)]
ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it has submitted a Special Protocol Assessment request to the U.S. Food and Drug Administration. The SPA submission is the next step in beginning a Phase 3 program fo
9/19/18 - argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia
argenx today announced positive topline results from its Phase 2 proof-of-concept clinical trial of efgartigimod in adult primary immune thrombocytopenia patients. The Phase 2 data of efgartigimod showed a favorable safety and tolerability profile consistent with the Phase 1 healthy volunteer trial and the Phase 2 proof-of-concept trial in...
9/19/18 - ASLAN Pharmaceuticals provides update on timelines for Clinical Trial of Varlitinib in Biliary Tract Cancer in China
SINGAPORE- ASLAN Pharmaceuticals, a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced an update to its planned timelines for the ongoing single-arm clinical trial in China testing varlitinib plus capecitabine in patients with...
9/19/18 - AstraZeneca - The Lancet Respiratory Medicine publishes first Phase III trial for PT010 triple combination therapy
The data were presented today at the European Respiratory Society International Congress 2018 in Paris, France, and published in The Lancet Respiratory Medicine.1. Dr Colin Reisner, Head of Respiratory, Global Medicines, said:' We are encouraged by the results of the KRONOS trial which demonstrate PT010's efficacy in improving lung function and its
9/19/18 - At 13% CAGR Clinical Trial Management Systems Market will touch USD 2.4 bn by 2024
"Key Players in the global CTMS market are Oracle Corporation, DATATRAK International, Merge Healthcare, MedNet Solutions, Parexel International Corp., Forte Research Systems, Medidata Solutions and Omnicomm Systems." UK Clinical Trial Management Systems Market will achieve remarkable growth over the forecast time period, driven by favorable govern
9/19/18 - Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Alzheimer's Disease Agitation
Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system disorders, today announced that it will host a research and development day with key opinion leaders on Thursday, October 18, 2018 in New York City. The event will feature presentations from Jeffrey Cumming
9/19/18 - Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Atezolizumab in Bladder Cancer [T-break Tech (Middle East)]
-Bavarian Nordic- sponsored study has commenced dosing. Study marks the second of three planned Phase 2 combination studies of CV301 with checkpoint inhibitors in solid tumors. COPENHAGEN, Denmark, September 18, 2018- Bavarian Nordic A/S today announced that the first patient has been dosed in a Phase 2 study evaluating the combination therapy of i
9/19/18 - BeiGene Announces Oral Data Presentations at Annual Meeting of the Chinese Society of Clinical Oncology
BEIJING- BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced four oral clinical data presentations on two of its late-stage investigational therapies, tislelizumab and zanubrutinib, at the 21st...
9/19/18 - Benitec Biopharma Announces the Appointment of Gregory R. Reyes, M.D., Ph.D. as Senior Scientific Advisor
Benitec Biopharma Limited, a clinical-stage biotechnology company developing novel genetic medicines via the proprietary DNA-directed RNA interference platform combining RNA interference with gene therapy, today announced that Gregory R. Reyes, M.D., Ph.D., has joined the company as Senior Scientific Advisor. Ph.D., Executive Chairman and Chief E
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415